Loading clinical trials...
Loading clinical trials...
A Phase 1/2 Study of [225Ac]-FPI-1966, [111In]-FPI-1967, and Vofatamab in Participants With FGFR3-expressing Advanced, Inoperable, Metastatic and/or Recurrent Solid Tumours
Conditions
Interventions
[225Ac]-FPI-1966
[111In]-FPI-1967
+1 more
Locations
6
United States
City of Hope
Duarte, California, United States
University of California, San Francisco
San Francisco, California, United States
University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
GC Murdoch
Murdoch, Western Australia, Australia
St Vincent's Hospital
Melbourne, Australia
Start Date
April 20, 2022
Primary Completion Date
September 8, 2023
Completion Date
September 8, 2023
Last Updated
December 19, 2023
NCT07177937
NCT05919264
NCT06532279
NCT07181681
NCT06257264
NCT07387068
Lead Sponsor
Fusion Pharmaceuticals Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions